REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Multicellular Living Organisms And Unmodified Parts Thereof And Related Processes > Nonhuman Animal > Transgenic Nonhuman Animal (e.g., Mollusks, Etc.) > Mammal > Mouse MouseMouse patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.11/15/07 - 20070266452 - Ksr2 knockout mice and methods of use thereof A transgenic non-human animal with a homologous disruption of the KSR-2 gene is disclosed. Methods for using transgenic mice so generated to screen for agents that effect cellular metabolism are also provided. ... 11/08/07 - 20070261127 - Light-activated cation channel and uses thereof The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention ... 10/25/07 - 20070250942 - Non-human transgenic mammals useful for identifying and assessing neural stem/progenitor cells Non-human transgenic mammals are produced which have, incorporated in their genome, DNA which includes a regulatory sequence of a mammalian nestin gene, operably linked to a gene coding for a nuclear localization signal peptide fused to a marker protein or reporter protein. The regulatory sequence can include a promoter and ... 10/18/07 - 20070245424 - Method for producing germ-line chimeric animal The present invention provides a method for efficiently producing a germ-line chimeric animal and a method for conveniently producing a heterozygous animal and a homozygous animal. Specifically, a chimeric animal wherein germ cells are derived from introduced ES cells is produced by injecting embryonic stem cells (ES cells) into an ... 09/20/07 - 20070220621 - Genetic characterization and prognostic significance of cancer stem cells in cancer The present invention is related to the identification of cancer stem cells using the MMTV-Wnt-1 transgenic mouse model. These cancer stem cells have a gene expression signature that allows them to be distinguished from their non-tumorigenic counterparts. Moreover, the gene expression pattern can also predict survival in a diverse group ... 08/30/07 - 20070204354 - Integrated in vivo animal experimentation systems The invention concerns methods for the development of mutant animals, including genetically engineered animals and those carrying spontaneous mutations, as human disease models. In particular, the invention provides an integrated technology, including rigorous specifications and quality control, for the development of animal models that can serve as a living assay ... 08/23/07 - 20070199084 - Ubiquitination of membrane transporters The present invention addresses methods of screening for ubiquination of membrane-bound transporters, such as SERT, NET and DAT. The ubiquitination of these transporters can regulate their turnover in the cell and trafficking to and from the plasma membrane, and thus provides a novel mechanism to modulate biogenic amine transporter activity. ... 08/23/07 - 20070199083 - Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis It is intended to provide a transgenic nonhuman mammal well representing the pathologic conditions of human rheumatoid arthritis. A transgenic nonhuman mammal is obtained by transferring a foreign DNA, wherein a DNA selected from the group consisting of an MHC class II transcriptional activator gene, the activity domain of an ... 08/23/07 - 20070199082 - Method of diagnosis of obesity The invention relates to new methods of diagnosis of obesity, in particular morbid obesity, based on the identification of polymorphism in an intron and/or the promoter region of the WAC gene, to method of screening potential obesity therapeutics, to pharmaceutical composition comprising said therapeutics, to transgenic non-human mammal. ... 08/09/07 - 20070186301 - Mutant bdnf gene introducing knockin mouse The invention relates to a non-human knockin animal having a mutation in a proBDNF gene wherein conversion from proBDNF to BDNF has been inhibited by the mutation. ... 08/09/07 - 20070186300 - Transgenic mouse capable of over-expressing ve-ptp The present invention relates generally to a transgenic mouse. In particular, the present invention relates to a transgenic mouse whose genome comprises a TetO-VE-PTP transgene. The present invention also relates to a double transgenic mouse whose genome comprises the transgenes TetO-VE-PTP and Tie2-tTA, which is capable of conditionally over-expressing VE-PTP ... 08/09/07 - 20070186299 - Knockout mouse for the tumor suppressor gene anx7 A knockout transgenic mouse containing a nonfunctional allele of the tumor suppressing gene, annexin VII. This mouse is used as a screening model for potential therapeutic agents useful in the treatment of tumors resulting from an annexin tumor suppressor disease. ... 07/26/07 - 20070174924 - Transgenic mice containing trp gene disruptions The present disclosure relates to compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising disruption in a trinucleotide repeat protein (TRP) gene. The present disclosure also provides methods of identifying agents that modulate TRP expression and function, useful models, and potential ... 07/12/07 - 20070162991 - Transgenic mice containing lrp5 gene disruptions The present disclosure relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising mutations in a low density lipoprotein-related protein 5 (Lrp5) gene. Such transgenic mice are useful as models for disease and for identifying ... 07/12/07 - 20070162990 - Neurodegenerative non-human transgenic mammal expressing trka fusion protein The present invention provides a neurodegenerative, non-human transgenic mammal whose cells contain a TrkA-hFc transgene for encoding at least a TrkA fusion protein and the use thereof. ... 07/12/07 - 20070162989 - Methods and compositions for treating motor neuron associated disorders The present invention provides a non-human animal (e.g., a mouse) that contains a plurality of genetically modified somatic cells (e.g., a motor neuron) having an exon 8 related loss-of-function modification in all WFS1 alleles. The present invention also provides a non-human animal that contains a plurality of genetically modified somatic ... 07/05/07 - 20070157330 - Reconstituted human breast tumor model Reconstituted human breast tumor models are disclosed. The models, which are incorporated into mice, provide actual tumors that arise spontaneously, thereby mimicking naturally occurring breast cancer. The tumors are genetically human, because they arise from human mammary tissues that develop from human mammary epithelial cells implanted into host mice. Prior ... 07/05/07 - 20070157329 - Amylases, nucleic acids encoding them and methods for making and using them In one aspect, the invention is directed to polypeptides having an amylase activity, polynucleotides encoding the polypeptides, and methods for malting and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention can be used as amylases, for example, alpha amylases, to catalyze the hydrolysis of starch ... 06/28/07 - 20070150974 - Transgenic non-human mammal with an oncogenic mutant of the c-raf-1 gene The invention relates to a transgenic non-human mammal whose cells express a constitutively active oncogenic mutant of the kinase-domain of the Raf-1 gene or a protein coded by a corresponding normal allele or derivative of the A, B, or c-Raf-1 gene. ... 06/28/07 - 20070150973 - Chimeric dna-binding proteins Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful. ... 06/21/07 - 20070143871 - Non-human transgenic animal models for hepatocellular carcinoma The invention relates to the field of non-human, transgenic animal models for hepatocellular carcinoma. ... 06/21/07 - 20070143870 - Spc7 serine protease gene disruptions, compositions and methods related thereto The present disclosure relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising mutations in an SPC7 serine protease gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate ... 06/21/07 - 20070143869 - Endotoxin-nonresponsive model animal The present invention is to provide a non-human animal model non-responsive especially to endotoxin being a Gram-negative bacteria cell wall fraction, which is useful to elucidate the function of TIR domain-containing TRIF-related adaptor molecule (TRAM); and a method for screening substances promoting or suppressing responses to ligands recognized by TLR4 ... 06/14/07 - 20070136833 - Genes encoding several poly (adp-ribose) glycohydrolase (parg) enzymes, the proteins and fragments thereof, and antibodies immunoreactive therewith The isolation and characterization of cDNAs encoding poly(ADP-ribose) glycohydrolase (PARG) enzymes and the amino acid sequences of PARGs from several species are described. PARG is involved in the cellular response to DNA damage and its proper function is associated with the body's response to neoplastic disorder inducing agents and oxidative ... 06/14/07 - 20070136832 - Novel lipoxygenase proteins and polynucleotides encoding the same The nucleotide and corresponding amino acid sequences are reported for a novel class of mammalian lipoxygenase proteins. The novel lipoxygenase encoding polynucleotides were obtained from human gene trap clones and human cDNA libraries. ... 06/07/07 - 20070130631 - Taar1 transgenic animal The present invention relates to genetic constructs comprising DNA encoding TAAR1 and their use to generate animals transgenic for TAAR1, transgenic animals comprising in their genome transgenic DNA encoding TAAR1, their use and methods of generating these animals. ... 05/31/07 - 20070124828 - Allelic form of the hmga2 gene predisposing women to the formation of leiomyomas The present invention is directed to diagnostic assays that can be used to determine if a woman carries an allelic form of the HMGA2 gene that predisposes her to the formation of fibroid tumors. The invention also encompasses vectors containing this allele, cells transformed with these vectors and transgenic animals ... 05/31/07 - 20070124827 - Type 2 diabetic non-human mammals and methods of use The invention provides a T2D mouse comprising a progeny from mating a C57BL/6 mouse and a DBA/2 mouse and exhibiting a blood glucose level of at least about 200 mg/dl, wherein the mouse is a non-human mammalian model predictive of human type 2 diabetes. The T2D mouse also can exhibit ... 05/24/07 - 20070118915 - Transgenic mice comprising a genomic human tau transgene The invention provides transgenic mice comprising tau transgenes, and methods of preparing and using the transgenic mice. For example, the invention provides a transgenic mouse, the genome of the cells of which stably comprise a DNA molecule which comprises a human genomic DNA sequence comprising a human tau promoter and ... 05/24/07 - 20070118914 - Oncohumouse The present invention includes a model system and use of the same for the study, manipulation and focusing of the human immune in a mammal, e.g., a nonhuman mammal that is immune deficient with one or more human hematopoietic progenitor cells and one or more human tumor cell lines. ... 05/17/07 - 20070113298 - Genetically determined mouse model of resistance to transplantable cancers We have established and studied a colony of mice with a unique trait of host resistance to both ascites and solid cancers induced by transplantable cells. One dramatic manifestation of this trait is age-dependent spontaneous regression of advanced cancers. This powerful resistance segregates as a single-locus dominant trait, is independent ... 05/10/07 - 20070107076 - Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo A non-human mammal having incorporated into its genome an expression construct in which nucleic acid encoding and oncogene is operably linked to an inducible promoter; the mammal further has a genetic mutation that causes it to have an increased susceptibility to cancer. ... 05/10/07 - 20070107075 - Disruptions in gaba receptor rho2 subunit, methods and uses thereof The present invention relates to compositions and methods relating to the characterization and function of GABRR2. Specifically, the present invention provides transgenic animals and methods of treating disease states or conditions in which the GABRR2 is implicated. The present invention also provides agents and method of identifying agents that modulate ... 05/03/07 - 20070101452 - Method for creating fusion protein and conditional alleles Gene trapping provides insertional mutagenesis strategies for monitoring the expression and localization of endogenous proteins. In accordance with the disclosure herein, a gene trapping vector and a method of fabrication and use are disclosed which provide for an efficient means of trapping and analyzing a gene of interest. ... 05/03/07 - 20070101451 - Llg polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also ... 04/19/07 - 20070089179 - Srebp2gc transcription factors and uses thereof The present invention relates to methods and compositions for modulating fertility. In particular the present invention provides cell lines and transgenic animals for use in identifying modulators of SREBP2gc transcription factors. The present invention further provides therapeutic agents that modulate SREBP2gc signaling for use as fertility modulators. ... 03/29/07 - 20070074300 - Sialidase inhibitors for the treatment of cardiovascular disease A method of treating or preventing a disorder associated with metabolic syndrome is provided. In particular, methods of treating atherosclerosis and diabetes by reducing sialidase activity are provided. ... 03/29/07 - 20070074299 - Transgenic mice containing gpcr5-1 gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a GPCR5-1 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 03/15/07 - 20070061909 - Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles The present invention describes a transgenic mouse susceptible to neuromuscular disease. The present invention also includes methods for treatment of neuromuscular diseases by interfering with activity between androgen and androgen receptors exclusively in the muscle fibers. ... 03/15/07 - 20070061908 - Transgenic animal for screening therapeutic agents for brain tumors A transgenic, non-human mammal useful for assessing the effect of candidate chemotherapeutic drugs on the growth of brain tumors in vivo is provided. Incorporated into the genome of the transgenic mammal, which preferably is a rodent, is a transgene which comprises a promoter comprising the nuclear factor binding region of ... 03/15/07 - 20070061907 - Inhibitor of differentiation knockout mammals and methods of use thereof The invention relates to Id knockout mammals having a disruption in at least one and at most three alleles of inhibitor of differentiation genes, Id1 and Id3. This results in reduction or prevention of a cell proliferative disorder in the mammal as compared to a wild-type mammal. In particular, tumor ... 03/08/07 - 20070056053 - Glucosidases, nucleic acids encoding them and methods for making and using them The invention is directed to polypeptides having a glucosidase activity, including an alpha-glucosidase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention are used as alpha-glucosidases to catalyze the hydrolysis of starch into sugars, e.g., to ... 03/01/07 - 20070050859 - Method of making a geneticaly modified mammalian cell A method of making a genetically modified mammalian cell, the method including selecting a first codon of a parent polynucleotide that encodes a polypeptide for replacement with a synonymous codon, wherein the synonymous codon is selected on the basis that it exhibits a higher translational efficiency in a first type ... 03/01/07 - 20070050858 - Inactive ca2+/calmodulin-dependent protein kinase ii-alpha knockin animal and knockin cell of the same The present invention provides an inactive Ca2+/calmodulin-dependent protein kinase IIα (CaMKIIα) knockin animal in which only the protein kinase activity of CaMKIIα, has been specifically impaired. Since CaMKIIα is considered to be involved in higher brain functions including learning and memory, and inhibit epileptic seizure and brain disorders caused by ... 02/22/07 - 20070044166 - P2y4 receptor transgenic and knockout non-human mammals This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according ... 02/22/07 - 20070044165 - Non-human mammal model comprising heterologous nucleated cells - use for screening compounds The invention relates to a method of malting a non-human mammal model comprising: a. implanting, into an immunocompromised non-human mammal host, heterologous nucleated cells previously bound to a biocompatible support, b. controlling non-adaptive defences of the non-human mammal host, c. recovering a non-human mammal model harbouring settled heterologous nucleated cells ... 02/15/07 - 20070039064 - Protein kinase c epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse The present invention relates to: cells and non-human animals deficient for the PKC isozyme ε (PKCε); the use of PKCε as a target for drugs; the use of inhibitors of PKCε in methods of reducing anxiety and treating conditions associated with insufficient activity of the GABAA receptor; the use of ... 02/15/07 - 20070039063 - Protein kinase c epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse The present invention relates to: cells and non-human animals deficient for the PKC isozyme ε (PKCε); the use of PKCε as a target for drugs; the use of inhibitors of PKCε in methods of reducing anxiety and treating conditions associated with insufficient activity of the GABAA receptor; the use of ... 02/08/07 - 20070033669 - Semaphorin gene family A novel class of proteins, semaphorins, nucleic acids encoding semaphorins, semaphorin peptides, and methods of using semaphorins and semaphorin-encoding nucleic acids are disclosed. Semaphorin peptides and receptor agonists and antagonists provide potent modulators of nerve cell growth and regeneration. The invention provides pharmaceutical compositions, methods for screening chemical libraries for ... 02/01/07 - 20070028316 - Transgenic non-human act1-deficient mammals and uses thereof The present invention provides a transgenic non-human mammal which lacks a functional Act1 gene referred to herein as a “transgenic non-human Act1 knockout mammal” or a “Act1 knockout mammal”. In a particular embodiment, the genome of the Act1 knockout mammal comprises at least one non-functional allele for the endogenous Act1 ... 02/01/07 - 20070028315 - Dna encoding snorf33 receptor This invention provides isolated nucleic acids encoding mammalian SNORF33 receptors, purified mammalian SNORF33 receptors, vectors comprising nucleic acid encoding mammalian SNORF33 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF33 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF33 receptors, antisense oligonucleotides complementary to unique sequences ... 02/01/07 - 20070028314 - Bone and/or joint disease-associated genes This invention provides a method for obtaining a gene involved in regulation of cartilage differentiation, in which a transcription factor, preferably Runx2/Cbfa1, is forcedly expressed in a cell that is deficient such transcription factor, preferably in a Runx2/Cbfa1-deficient chondrocyte, and the gene, the expression of which is thereby induced, is ... 01/25/07 - 20070022488 - Mouse model for aging A mouse model for mammalian aging is disclosed. In one embodiment, the invention comprises a mouse having a genomic mutation in the exonuclease domain II (ExoII) of a mitochondrial DNA polymerase gamma (POlG) gene, wherein the mutation leads to high levels of mutations in polymerase mtDNA. ... 01/25/07 - 20070022487 - Huntingtin interacting protein gene disruptions, compositions and methods related thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a HIP1 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 01/25/07 - 20070022486 - Proliferator-activated receptor disruptions, compositions and methods relating thereto The present disclosure relates to compositions, including transgenic and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising mutations in a PPAR gene. The present disclosure also provides methods for identifying agents that modulate PPAR expression and function, useful models, and potential treatments ... 01/25/07 - 20070022485 - Method of preparing transgenic organism with use of methylation and system therefor A technique for efficiently introducing a foreign gene into cells with the use of transposons. In particular, a technique for efficiently preparing a transgenic organism with the use of a transposon having its transposition activity strikingly enhanced through methylation of a sequence containing the transposon. The methylation is retained even ... 01/11/07 - 20070011758 - Mouse with deficiency of glutamate transporter glast function The present invention provides a GLAST knockout mouse lacking the function of an endogenous glutamate transporter GLAST gene, which shows: 1) an intraocular pressure within the normal range; and 2) a reduction in the number of cells in the retinal ganglions when compared with a wild-type normal mouse. Owing to ... 12/28/06 - 20060294615 - Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer Presented is a therapeutic method to treat prostate carcinomas in mammals comprising the administration of cellular PAcP protein. Also presented is a method to diagnose androgen-insensitive prostate carcinomas by determining the expression level of cellular PAcP in the prostate carcinomas, a decrease in expression being indicative of androgen-insensitivity. A promoter ... 12/28/06 - 20060294614 - Murine genomic polynucleotide sequence encoding a g-protein coupled receptor and methods of use therefor The present invention particularly relates to a newly identified murine genomic polynucleotide that encodes an ortholog of the human P2T receptor which is expressed at high levels in the central nervous system, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. The ... 12/28/06 - 20060294613 - Mo54 disruptions, compositions and methods related thereto The present disclosure relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising mutations in a Mo54 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 12/28/06 - 20060294612 - Gpcr-like retinoic acid-induced gene 1 protein and nucleic acid A novel G-protein coupled receptor-like retinoic acid induced molecule was identified as being differentially expressed (GPCR-like RAIG1) in an animal model of fasting and feeding. Compositions and methods pertaining to treatment and diagnosis of various metabolic disorders, such as cachexia and obesity. ... 12/28/06 - 20060294611 - Wip, a wasp-associated protein Described herein is a novel gene and its product, WIP, which associates with WASP. The subject invention relates to the isolated WIP gene or cDNA and transgenic mammals that have the WIP gene disrupted in their genome. Also the subject of this invention are methods of treating conditions or diseases ... 12/21/06 - 20060288437 - Zinc finger-based drug-dependent gene regulation system The invention is based on the discovery that one can create a drug-regulated gene regulation system by creating a fusion polypeptide or chimera that includes three portions: a zinc finger (ZF) protein that recognizes and binds to a nucleic acid recognition sequence in the vicinity of a promoter of the ... 12/21/06 - 20060288436 - Screening systems and methods for identifying modulators of xenobioticmetabolism The present invention provides mice having reduced CAR receptor activity and mice expressing a human CAR receptor. These mice are useful in screening methods to identify compounds that modulate CAR receptor activity, compounds likely to have CAR-mediated toxicity, and analogs of these compounds with less potential toxicity. ... 12/21/06 - 20060288435 - Cd9/cd81 double-deficient non-human animal An object of the invention is to provide a non-human animal which can be utilized as a model animal well exhibiting a pathological condition of low-turnover type of osteoporosis and chronic obstructive pulmonary disease, for screening therapeutic agents for osteoporosis or therapeutic agents for chronic obstructive pulmonary disease, etc. The ... 12/21/06 - 20060288434 - Artery-and vein-specific proteins and uses therefor Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a ... 11/30/06 - 20060272041 - Cathepsin g (ctsg) disruptions, compositions and methods relating thereto The present disclosure relates to compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising disruption in a CTSG. The present disclosure also provides methods of identifying agents that modulate CTSG expression and function, useful models, and potential treatments for various disease ... 11/23/06 - 20060265772 - Histamine hyperproductive animal The invention of the present patent application provides, a histamine-hyperproductive animal, which is a non-human animal or progeny thereof obtained by ontogenesis of totipotent cells transfected with a polynucleotide encoding histidine decarboxylase and has the above polynucleotide in the cellular chromosome to produce histamine at a high level in the ... 11/23/06 - 20060265771 - Monitoring microrna expression and function In vivo endogenous microRNA (miRNA) activity can be observed over time using miRNA sensor plasmids capable of long term expression. Using reporter genes whose expression can be monitored without sacrificing the animal enables the investigator to follow changes in miRNA expression though developmental stages or in response to environmental factors ... 11/23/06 - 20060265770 - Transgenic mice containing glutamate receptor (grik5) gene disruptions The present disclosure relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising mutations in a GRIK5 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 11/23/06 - 20060265769 - Gab2 (p97) gene and methods of use thereof This invention relates to the purification, cloning and characterization of a novel gene, Gab2. In response to extracellular stimuli (e.g., cyokines, growth factors, hormones and antigens), Gab2 binds several signal relay molecules, including the protein-tyrosine phosphatase SHP-2 and phosphatidylinositol-3-OH kinase (PI-3K), which results in the initiation of multiple signaling cascades. ... 11/16/06 - 20060259996 - Single domain tdf-related compounds and analogs thereof The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders. ... 11/16/06 - 20060259995 - Proteases, nucleic acids encoding them and methods for making and using them The invention is directed to polypeptides having protease activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of diagnostic, therapeutic, and industrial contexts. The polypeptides of the invention can be used as, e.g., ... 11/16/06 - 20060259994 - Cathepsin-associated genetically modified nonhuman mammal Disclosed are a cathepsin E gene and a non-human mammalian animal with the cathepsin E-associated gene altered. The cathepsin E-associated gene and the DNA fragment thereof have each a base sequence or a partial amino acid sequence as identified by SEQ ID #1. The cathepsin E-associated gene-altered non-human mammalian animal ... 11/16/06 - 20060259993 - Amidases, nucleic acids encoding them and methods for making and using them This invention provides amidases, polynucleotides encoding the amidases, methods of making and using these polynucleotides and polypeptides. In one aspect, the invention provides enzymes having secondary amidase activity, e.g., having activity in the hydrolysis of amides, including enzymes having peptidase, protease and/or hydantoinase activity. In alternative aspects, the enzymes of ... 11/09/06 - 20060253915 - Transgenic mice containing kir3.3 potassium channel gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a Kir3.3 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 11/09/06 - 20060253914 - Ha4,a new osteoblast-and chondrocyte-specific small secreted peptide, compositions and methods of use A polypeptide designated HA4, expressed selectively by bone tissue, is provided. Transgenic animals that fail to express HA4 have bone formation abnormalities reflective of osteoporosis, Also provided are methods for promoting bone formation by increasing the activity or expression of HA4, methods of diagnosing or treating bone degenerative diseases, and ... 11/02/06 - 20060248607 - Ccr6 chemokine receptor disruptions, compositions and methods relating thereto The present disclosure relates to compositions and methods relating to the characterization and function of CCR6. Specifically, the present disclosure provides transgenic animals comprising disruptions in a CCR6 gene and methods of treating diseases conditions, such as pain, inflammatory bowel disease, rheumatoid arthritis and contact dermatitis. The present disclosure further ... 10/26/06 - 20060242725 - Cell-specific molecule and method for importing dna into osteoblast nuclei A plasmid, viral or linear DNA molecule containing a nucleic acid sequence derived from the promoter region of the hCol1α2 gene, which is selectively transported into the nuclei of cells in the osteoblast lineage. The sequence can be used independently as a nuclear entry sequence only, and/or as a nuclear ... 10/26/06 - 20060242724 - Receptor The present invention relates to novel functions of a known receptor. In particular, the invention relates to the use of a sphingosylphosphorylcholine receptor and/or ligands thereof in the manipulation of the neuronal and limbic systems and diagnosis and treatment of pain. ... 10/26/06 - 20060242723 - Chimeric mouse with regulated bradeion gene expression The present invention relates to a chimeric mouse having an endogenous Bradeion gene, the gene expression of which has been suppressed, and a cell derived from a mouse embryonic stem cell, which is collected from such chimeric mouse. ... 10/19/06 - 20060236418 - Genetically modified non-human mammals and cells A genetically modified non-human mammal or cell characterised in that it does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region locus polypeptide. ... 10/19/06 - 20060236417 - Transgenic mammal carrying ganp gene transferred thereinto and utilization thereof It is an object of the present invention to provide a high affinity antibody effective as a diagnostic or therapeutic for various diseases; a transgenic mammal for producing the high affinity antibody; and a medicine comprising the high affinity antibody or a cell producing the high affinity antibody. According to ... 10/19/06 - 20060236416 - Embryonically modified animal and method of constructing the same The present invention relates to a method for efficiently producing a reproducible animal using totipotent cells wherein mitochondrial DNAs (e.g., wild-type DNAs) adapted to nuclear DNAs have been introduced into or substituted with mitochondrial DNAs, and the present invention also relates to an animal obtained by such production method. When ... 10/12/06 - 20060230466 - Gene-targeted animal model of apolipoprotein e4 domain interaction and uses thereof The invention provides gene-targeted non-human animals comprising a genetically modified apoE gene encodes a recombinant apoE polypeptide displaying domain interaction. The invention further provides cells isolated from the gene-targeted animals, which cells produce a recombinant apoE polypeptide displaying domain interaction. The invention further provides methods of identifying agents that reduce ... 09/28/06 - 20060218656 - Transgenic mice containing mglur7 metabotropic glutamate receptor gene disruptions The present disclosure relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising mutations in an mGluR7 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 09/28/06 - 20060218655 - Transgenic mice expressing human cd20 and/or cd16 The present invention generally relates to non-human transgenic animals expressing human cellular markers, including CD20 and/or preferably CD16. ... 09/28/06 - 20060218654 - Sirna mediated gene silencing in transgenic animals The present invention relates to a process that enables constitutive and inducible gene knock down in living organisms using a short hairpin RNA expression vector integrated into the genome of the organism. ... 09/21/06 - 20060212957 - Transgenic non-human mammal with an oncogenic mutant of the c-raf gene 1 The invention relates to a transgenic non-human mammal whose cells express a constitutively active oncogenic mutant of the kinase-domain of the Raf-1 gene or a protein coded by a corresponding normal allele or derivative of the A, B, or c-Raf-1 gene. ... 09/21/06 - 20060212956 - Animal model of ligand activated her2 expressing tumors The invention concerns animal models of ligand activated HER2-expressing tumors. This model is useful for evaluating the efficacy of various therapeutic approaches for the treatment of such tumors. ... 09/21/06 - 20060212955 - Transgenic mice containing lymphoid-specific gpcr gene disruptions The present disclosure relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising disruptions in lymphoid-specific GPCR genes. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 09/21/06 - 20060212954 - Mouse model for aging A mouse model for mammalian aging is disclosed. In one embodiment, the invention comprises a mouse having a genomic mutation in the exonuclease domain II (ExoII) of a mitochondrial DNA polymerase gamma (PolG) gene, wherein the mutation leads to high levels of mutations in polymerase mtDNA. ... 09/21/06 - 20060212953 - Tr2, tr4, tr2/tr4 double knockouts and uses thereof Disclosed are compositions and methods for disrupting an testicular orphan nuclear receptor 2. ... 09/14/06 - 20060206951 - Gaba b1a receptor disruptions, compositions and methods relating thereto The present disclosure relates to compositions and methods relating to the characterization, function, and uses of GABA-B1A. Specifically, the present disclosure provides transgenic animals comprising disruptions in GABA-B1A receptors. The present disclosure also provides methods of identifying agents that modulate GABA-B1A, useful models, and potential treatments for various disease states ... 09/14/06 - 20060206950 - In vivo imaging of e2f-fegulated bioluminescent proteins The present invention relates to transgenic animals, as well as compositions and methods relating to the identification of prolifering cells. Specifically, the present invention provides transgenic mice having a nucleic acid comprising an E2F responsive promoter operably linked to a nucleic acid encoding a bioluminescent protein. Such transgenic mice are ... 09/07/06 - 20060200871 - Transgenic non-human animals with expanded mature b cell and plasma cell populations Transgenic non-human animals with expanded mature B cell and plasma cell populations are described, as well as methods of using the transgenic non-human animals to screen for pharmaceutically active agents and to produce targeted antibodies. ... 08/17/06 - 20060185028 - Transgenic mice containing socs-5 cytokine signalling suppressor gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a SOCS-5 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 08/10/06 - 20060179505 - Transgenic mice containing channel activating protease 1 (cap1) gene disruptions The present disclosure relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising mutations in a CAP1 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 08/10/06 - 20060179504 - Transgenic mice containing deubiquitinated enzyme gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a deubiquitin protease-like gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene ... 08/10/06 - 20060179503 - Transgenic mice containing msk2 serine/threonine kinase gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a MSK2 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 08/10/06 - 20060179502 - Automated gene-targeting using non-toxic detectable markers The invention relates to a method that enables automated identification and isolation of cells harbouring a predetermined genetic modification (homologous recombination) using detectable/sortable markers, e.g. fluorescence markers, to identify homologous DNA modifications. Suitable vectors are also provided. ... 08/10/06 - 20060179501 - Transgenic mice expressing human cd20 The present invention generally relates to non-human transgenic animals expressing human cellular markers, including CD20 and methods for using the animals to identify agents that are effective to deplete cells bearing human CD20. The transgenic animals are also useful to test safety and efficacy of anti-CD20 therapies. ... 08/03/06 - 20060174361 - Transgenic mice containing adrenocorticotropin hormone receptor gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an ACTHR gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 08/03/06 - 20060174360 - Non-inbred embryonic stem cells having good developmental potential The present invention provides non-inbred mouse embryonic stem (ES) cells comprising alleles derived from at least two different mouse strains and having high developmental potential. The ES cells optionally comprises a docking site for a transgene. Methods for production of the ES cells are also disclosed. This invention further provides ... 07/27/06 - 20060168674 - Mouse cardiac conduction system model The present invention relates to a transgenic mouse which has integrated a reporter gene in the locus of the Cx40 gene, wherein said reporter gene is expressed in the different components of the cardiac conduction system (CCS) including the atrio-ventricular node (AVN). His bundle, bundle branches and Purkinje fibers. ... 07/20/06 - 20060162004 - Adam-like protease disruptions, compositions and methods related thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an ADAM-like protease gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene ... 07/13/06 - 20060156426 - Transgenic mice containing abc transporter-like atpase gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an ABC transporter-like ATPase gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate ... 07/13/06 - 20060156425 - Gng4 gene disruptions, compositions and methods related thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a GNG4 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 07/06/06 - 20060150266 - Trp6 calcium channel disruptions, compositions and methods related thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a TRP6 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 07/06/06 - 20060150265 - Transgenic mice containing sulfotransferase gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in sulfotransferase genes. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and ... 07/06/06 - 20060150264 - Differential gene expression in schizophrenia The invention relates to methods of identifying potential therapeutic agents for the prevention, treatment, or amelioration of schizophrenia, to methods of diagnosis of schizophrenia, to methods of identifying patients most likely to respond to a particular therapeutic treatment, to methods for selecting participants in clinical trials, and to methods of ... 06/29/06 - 20060143724 - Transgenic mice containing anaphylatoxin c3a gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an anaphylatoxin C3a receptor gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate ... 06/29/06 - 20060143723 - Use of glucose-6-phosphate isomerase and antibodies thereto for the diagnosis and therapy of arthritis, and test of anti-arthritic compounds The present invention relates to the use of antibodies against glucose-6-phosphate isomerase (GPI) and like protein for diagnosis of arthritis and the use of said protein for treatment of arthritis. It is also aimed at a process for isolating monoclonal antibodies capable of transferring arthritis and antibodies thereof, as well ... 06/29/06 - 20060143722 - Ogr1 gene disruptions, compositions and methods relating thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an OGR1 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 06/29/06 - 20060143721 - Transgenic mice containing tryptase gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a tryptase gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 06/29/06 - 20060143720 - Transgenic mice containing chordin gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a chordin gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 06/22/06 - 20060137031 - Transgenic mice containing retinoid x receptor interacting protein gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in the LXRB gene. Such transgenic mice are useful as models for disease, such as diabetes. The present invention is also ... 06/22/06 - 20060137030 - Protein tyrosine phosphatase rptp-beta disruptions, compositions and methods relating thereto The present invention relates to compositions and methods relating to the characterization and function of RPTPB. Specifically, the present invention provides transgenic animals comprising disruptions in a RPTPB gene and methods of treating diseases conditions, such as depression. The present invention further relates to agents that modulate RPTPB and methods ... 06/15/06 - 20060130169 - Transgenic non-human mammals as models for human pathologies of stem cell origin Transgenic non-human mammals that reproduce human pathologies of stem cell origins, such as chromosomal anomalies associated with chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, T-cell acute or lymphoblastic leukemia, or with the migration of hematopoietic or embryonic stem calls. The transgenic non-human mammals can be produced using as a strategy ... 06/15/06 - 20060130168 - Transgenic non-human mammals as models for human pathologies of stem cell origin Transgenic non-human mammals that reproduce human pathologies of stem cell origins, such as chromosomal anomalies associated with chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, T-cell acute or lymphoblastic leukemia, or with the migration of hematopoietic or embryonic stem calls. The transgenic non-human mammals can be produced using as a strategy ... 06/15/06 - 20060130167 - Transgenic non-human mammals as models for human pathologies of stem cell origin Transgenic non-human mammals that reproduce human pathologies of stem cell origins, such as chromosomal anomalies associated with chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, T-cell acute or lymphoblastic leukemia, or with the migration of hematopoietic or embryonic stem calls. The transgenic non-human mammals can be produced using as a strategy ... 06/15/06 - 20060130166 - Transgenic non-human mammals as models for human pathologies of stem cell origin Transgenic non-human mammals that reproduce human pathologies of stem cell origins, such as chromosomal anomalies associated with chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, T-cell acute or lymphoblastic leukemia, or with the migration of hematopoietic or embryonic stem cells. The transgenic non-human mammals can be produced using as a strategy ... 06/15/06 - 20060130165 - F066 transgenic mice that express pathogenic mutants of the sca2 gene The present invention is related with the neurobiology and the transgenic animals, more specifically with obtaining a model to study the SCA2 genetic disease. The genome of one mice line has been modified through the introduction of a DNA segment that contains the necessary information for the synthesis of the ... 06/15/06 - 20060130164 - Toll/interleukin-1 receptor adapter protein (tirap) TIRAP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TIRAP polypeptides and polynucleotides in therapy, and diagnostic assays for such. ... 06/08/06 - 20060123503 - V1a arginine vasopressin receptor disruptions, compositions and methods relating thereto The present invention relates to compositions and methods relating to the characterization and function of V1a vasopressin receptor. Specifically, the present invention provides transgenic animals comprising disruptions in a V1a vasopressin receptor gene and methods of treating diseases conditions, such as schizophrenia, diabetes and inflammatory bowel disease. The present invention ... 06/01/06 - 20060117399 - Animal model for human lymphomas This invention develops the first mouse model for human lymphomas with mutations in the NF-KB2 gene that can be used for the study of the pathogenesis of this subset of lymphomas and for the development and testing of therapeutic and prevention drugs. The mice develop B- and T-cell lymphomas with ... 05/25/06 - 20060112441 - Cyt28 serpentine receptor disruptions, compositions and methods relating thereto The present invention relates to compositions and methods relating to the characterization and function of CYT28. Specifically, the present invention provides transgenic animals comprising disruptions in a CYT28 gene and methods of treating diseases conditions, such as pain. The present invention further relates to agents that modulate CYT28 and methods ... 05/25/06 - 20060112440 - Fluorescent protein sensors for detection of analytes Fluorescent indicators including a binding protein moiety, a donor fluorescent protein moiety, and an acceptor fluorescent protein moiety are described. The binding protein moiety has an analyte-binding region which binds an analyte and causes the indicator to change conformation upon exposure to the analyte. The donor moiety and the acceptor ... 05/25/06 - 20060112439 - Delta opioid receptor disruptions, compositions and methods related thereto The present disclosure relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising mutations in a delta-opioid receptor gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene ... 05/18/06 - 20060107341 - Inducible eukaryotic expression system Compositions and methods for the inducible expression of genes in eukaryotic cells. Expression of a nucleotide sequence of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When the cognate ligand for the ligand-binding domain is present, transcription of the ... 05/18/06 - 20060107340 - Calpain large subunit (n-cl4) cysteine protease gene disruptions, and compositions and methods related thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an n-CL4 cysteine protease gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate ... 05/18/06 - 20060107339 - Transgenic animal expressing hla-a24 and utilization thereof The present invention relates to a non-human transgenic mammal which has had an HLA-A24 gene introduced and in which CTLs are induced when stimulated by an HLA-A24-binding antigen, a method of screening therapeutic or preventive agents for tumors or virus infections comprising administering a test substance to said transgenic non-human ... 05/18/06 - 20060107338 - Hepatic cirrhosis model animal and method of constructing the same The present invention provides a cirrhosis model animal having human hepatic tissues affected with cirrhosis. Anti-asialo GM1 antibodies are administered to a scid mouse which is an immune-deficiency animal, and its natural-killer-cell-dependent immune response capability is made defective, and then cirrhosis-patient-derived hepatic tissues are transplanted beneath a kidney membrane of ... 05/11/06 - 20060101534 - Transgenic mice containing beta3galt2 gene disruptions The present disclosure relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising mutations in a β3GalT2 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 05/11/06 - 20060101533 - Transgenic mice containing tmem3 beta-1,3-n-acetylglucosaminyltransferase gene disruptions The present disclosure relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising mutations in a TMEM3 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 05/04/06 - 20060095979 - Transgenic mice containing clcn4 chloride ion channel gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a CLCN4 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 04/27/06 - 20060090214 - Method of treatment and an animal model useful for same The present invention relates generally to a method of treatment and to an animal model for the identification of molecules and genetic sequences useful in method of treatment including inducing or reducing fertility of male animals. More particularly, the present invention contemplates a method for the treatment of infertility or ... 04/27/06 - 20060090213 - Transgenic mice containing kir5.1 inwardly rectifying potassium channel gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a Kir5.1 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 04/27/06 - 20060090212 - Novel human genes and proteins encoded thereby The present invention relates to novel human genes involved in the regulation of signal transduction pathways, and the proteins and polypeptides encoded thereby. In particular, the invention relates to polynucleotides that encode the polypeptides, the polypeptides, antibodies directed to the polypeptides, and methods of diagnosis and treatment of various disorders, ... 04/20/06 - 20060085866 - Method for generating an animal homozygous for a genetic modification Methods of generating modified embryos and mammals by introduction of donor cells into an early stage embryo are provided, such that the resulting embryo and animal generated therefrom has a significant or complete contribution to all tissues from the donor cells and is capable of transmitting the donor cell DNA. ... 04/20/06 - 20060085865 - Transgenic mice containing gpcr-like gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a GPCR-like gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 04/06/06 - 20060075512 - Transgenic mice containing pafr gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a platelet-activating factor receptor gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate ... 04/06/06 - 20060075511 - Muir-torre-like syndrome in fhit deficient mice The invention provides nonhuman transgenic animals with a disrupted FHIT gene. The invention further provides transgenic mice in which one or both Fhit alleles have been inactivated. Preferably, the Fhit-deficient mice develop multiple tumors of both visceral and sebaceous origin, similar to those of Muir-Torre familial cancer syndrome. The present ... 04/06/06 - 20060075510 - Murine genomic polynucleotide sequence encoding a g-protein coupled receptor and methods of use therefor The present invention particularly relates to a newly identified murine genomic polynucleotide that encodes an ortholog of the human P2T receptor which is expressed at high levels in the central nervous system, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. The ... 03/30/06 - 20060070136 - Glyt1 transgenic mouse The present invention provides genetic constructs and methods for producing transgenic non-human animals comprising within their genome transgenic DNA encoding GLYT1. These transgenic animals could be further used to generate transgenic animals which produce more active GLYT1. Also provided are transgenic animals producing more GLYT1 protein, as well as the ... 03/30/06 - 20060070135 - Compositions and methods for inhibiting the enzymatic activity of ptp-1b The present invention provides mice that have had their PTP-1B genes disrupted by targeted homologous recombination. The mice have no detectable PTP-1B protein, yet appear to be physiologically normal. However, in the fed state on a normal diet, the mice have half the level of circulating insulin as their wild-type ... 03/23/06 - 20060064770 - Methods for identifying a cell or an embryo carrying a y chromosome Methods for modifying a mammalian cell target such that the presence of a Y chromosome is detectable. The method includes construction of a targeting vector with a detectable marker that can recombine or insert into a pre-selected site on the Y chromosome, allowing the presence of the Y chromosome to ... 03/23/06 - 20060064769 - Conditional disruption of dicer1 in cell lines and non-human mammals The present invention is based, at least in part, on the generation of cells, cell lines and non-human mammals that contain a synthetic conditional allele of the Dicer1 gene. Many of the constructs, methods, animals and cells of the invention feature recombinase recognition sites (in certain embodiments, loxP sites) positioned ... 03/23/06 - 20060064768 - Murine pten null prostate cancer model The invention provides a transgenic mouse and cell lines with a homozygous disruption of a chromosomal PTEN gene in prostate cells. The mouse progresses from hyperplasia to metastatic cancer and can be used to identify prostate cancer therapeutics and genes that are differentially regulated during androgen dependent and androgen independent ... 03/23/06 - 20060064767 - Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy It is intended to provide a model animal faithfully reproducing the pathogenic conditions of spinal and bulbar muscular atrophy, a method of screening a remedy for polyglutamine disease using the same, and a remedy for spinal and bulbar muscular atrophy. Namely, a nonhuman animal having the following characteristics (1) to ... 03/23/06 - 20060064766 - Histamine receptor h3 modified transgenic mice A transgenic animal with alterations in the histamine H3 receptor gene is prepared by introduction of an altered histamine H3 receptor gene into a host animal. The resulting transgenic animals do not produce functional histamine H3 receptor molecules. Cells and cell lines derived from these animals also contain the altered ... 03/16/06 - 20060059579 - Model animals non-responsive to mycobacteria-origin lipoprotein/lipopeptide The present invention is to provide TLR1 knockout mice specifically recognizing mycobacterial lipoproteins/lipopeptides, being useful to clarify the role of TLR1 in vivo, or a method for screening substances promoting or suppressing the response to mycobacterial lipoproteins/lipopeptides by using the same. TLR1 genes are separated from murine genomic library, the ... 03/16/06 - 20060059578 - Adiponectin-knoucout nonhuman animal The animals of the present invention enable elucidation of the onset mechanisms of obesity, diabetes, and arteriosclerosis. Moreover, they are useful for screening preventive and therapeutic drugs for treating any of these diseases. ... 03/09/06 - 20060053503 - Cranial and vertebral defects associated with loss-of-function of nell The mouse Nell1 cDNA and amino acid sequences are disclosed. Also disclosed is a Nell1 knock-out mouse with several bone- and cartilage-related defects. On the molecular level, the loss of Nell1 function led to reduced expression of certain extracellular matrix proteins. The disclosure here provides new tools for studying bone ... 03/02/06 - 20060048238 - Transgenic tieg non-human animals Materials and methods related to a transgenic non-human animal (e.g., a transgenic non-human mammal) whose genome comprises a disrupted TIEG allele are provided. Methods for making such transgenic non-human animals, and using them to identify and characterize agents that affect conditions related to TIEG activity, such as cardiac hypertrophy and ... 02/23/06 - 20060041948 - Transgenic mice containing chemokine receptor 9a gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a chemokine receptor 9A gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate ... 02/23/06 - 20060041947 - Nessie nucleic acids, polypeptides and mutations, and methods of use thereof The present invention relates to the discovery, identification, and characterization of novel genes encoding proteins that play a role in immune system development and function, collectively termed Nessie. The invention encompasses the described polynucleotides, the encoded proteins, fusion proteins, polypeptides and peptides, genetically engineered animals that either under- or over-express ... 02/16/06 - 20060037094 - Secreted protein associated with depression, compositions and methods of use thereof The present invention relates to compositions and methods relating to the characterization of gene function. More particularly, the present invention relates to the role of secreted protein genes involved in neurobiological disorders, and in particular, depression. In addition, the present invention provides transgenic mice comprising mutations in a secreted protein ... 02/16/06 - 20060037093 - Transgenic transchromosomal rodents for making human antibodies The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies. ... 02/16/06 - 20060037092 - Universal stem cells The subject invention pertains to materials and methods for preparing multi-potential stem cells having a pre-selected expression of MHC antigens. Stem cells of the subject invention can be used to generate histocompatible tissues/organs for transplantation. The process of the subject invention comprises the use of targeting vectors capable of gene ... 02/16/06 - 20060037091 - Method for producing hypertrophic scarring animal model for identification of agents for prevention and treatment of human hypertrophic scarring The present invention relates to a method of producing a non-human animal model of hypertrophic scarring. This involves producing an incision in a non-human animal and applying mechanical strain over the incision under conditions effective to produce hypertrophic scarring, thereby producing a non-human animal model of hypertrophic scarring. The present ... 02/09/06 - 20060031954 - Fcrn-based therapeutics for the treatment of auto-immune disorders Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene. The homozygous FcRn disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse in which exogenously administered IgG1 exhibits a substantially shorter half-life, as compared to the half-life ... 02/09/06 - 20060031953 - Procollagen iia deficient mice This invention relates to the production of dual models of Congenital Heart Defects and Hypertrophic Cardiomyopathy with the use of mice which are genetically modified by transgenic (gene-knockout) techniques. The present invention produces knockout mice that show multiple cardiovascular malformations which will serve as a model of cardiovascular diseases for ... 02/02/06 - 20060026703 - Transgenic non-human animals for producing heterologous and chimeric antibodies The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity. ... 02/02/06 - 20060026702 - Phosphoinositide 3-kinase mediated inhibition of gpcrs The present invention relates to compounds that alter GPCR internalization and new methods for their identification. Compounds of this invention include modified phosphoinositide 3-kinase (PI3K), modified HEAT domain, modified β-adrenergic receptor kinase 1 (βARK1), as well as other peptides or small molecules that alter GPCR internalization. The present invention also ... 01/26/06 - 20060021075 - Group 1 cd1 transgenic mice and their uses Disclosed are compositions and methods relating to a human group 1 CD1 transgenic mouse. ... 01/26/06 - 20060021074 - Reducing the risk of human anti-human antibodies through v gene manipulation The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for ... 01/26/06 - 20060021073 - Noc2 knockout mouse Disclosed are a mouse homozygous or heterozygous for the defect of the Noc2 gene, and a tissue and a cell of the mouse. The Noc2 knockout mice, which exhibit stress-related insulin hyposecretion and accumulation of secretory granules of increased size and irregular shape in exocrine cells, provide a test system ... 01/26/06 - 20060021072 - Mouse model for type ii diabetes The present invention relates to a Type II diabetes model mouse, having a causative gene responsible for the following characteristics (1) to (3) in the heterologous or homologous state, wherein the characteristics are autosomal recessive genetic traits: (1) having a higher blood sugar level as compared to a normal strain ... 01/19/06 - 20060015959 - Transgenic animals expressing transglutaminase ii The invention provides transgenic, non-human animals and transgenic non-human mammalian cells harboring a transgene encoding a TGII (activator of the protein kinase cdk 5) polypeptide. The two neuropathological lesions associated with Alzheimer's disease (AD) are amyloid plaques and neurofibrillary tangles (NFTs), composed predominantly of amyloid β peptides and hyperphosphorylated tau, ... 01/19/06 - 20060015958 - Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing ... 01/19/06 - 20060015957 - Transgenic non-human animals for producing chimeric antibodies The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity. ... 01/12/06 - 20060010509 - Methods and compositions for producing germ cells from bone marrow derived germline stem cells The present invention relates to the use of bone marrow derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof. ... 01/12/06 - 20060010508 - Compositions comprising female germline stem cells and methods of use thereof The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof. ... 01/12/06 - 20060010507 - Endophilin iii gene disruptions, compositions and methods related thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an endophilin III gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene ... 12/29/05 - 20050289661 - Cxcr6 chemokine receptor gene disruptions, and compositions and methods related thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a CXCR6 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 12/29/05 - 20050289660 - Cyclic amp phosphodiesterase 4d7 isoforms and methods of use Human, rat and mouse cAMP phosphodiesterase isoforms (denoted PDE4D7s), as well as the DNA (RNA) encoding such polypeptides, are disclosed. Also disclosed are methods for utilizing such polypeptides in diagnostic assays for identifying mutations in nucleic acid sequences encoding the polypeptides of the present invention, for detecting altered levels of ... 12/22/05 - 20050283846 - Method for evaluating therapeutic agent for dermatitis and/or alopecia, therapeutic agent for dermatitis and/or alopecia, and transgenic mouse A method for evaluating an effect of an agent to be tested on alopecia, using a transgenic mouse to which an interleukin-18 gene under control of a keratinocyte promoter is introduced, or a method for evaluating an effect of an agent to be tested on skin, using the transgenic mouse, ... 12/15/05 - 20050278798 - Method of breeding laboratory animals to optimize tumor suppression and tissue repair functions in vivo and improved methods for conducting experiments and safety testing Animals such as mice used in laboratory tests are breed in such a way that the distribution of telomeres yields improved results. This can be accomplished by randomly assigning a breeding period to each animal, by otherwise influencing telomere distribution or by providing multiple populations of animals with different characteristics. ... 12/15/05 - 20050278797 - Transgenic cell and gene recombinant animal having a mutant sdhc gene derived from mammals It is an object of the present invention to provide a transgenic cell and gene recombinant animal having a mutant SDHC gene, which enables the examination of the action of reactive oxygen species (ROS) derived from mitochondria in mammals. The present invention provides a transgenic animal cell and a gene ... 12/08/05 - 20050273871 - Method for diagnosing arrhythmogenic right ventricular dysplasia A specific strain of KK obese mice was found to show a phenotype peculiar to human arrythomogenic right ventricular dysplasia (ARVD), and Lamrl-functional transposon 1 (Lamr1-tp1) was determined to be responsible for this phenotype. Furthermore, the translation product of Lamr1-tp1 was shown to interact with HP1-alpha. Together with the knowledge ... 12/01/05 - 20050268350 - Identification and purification of higher order transcription complexes from transgenic non-human animals The invention relates to transgenes comprising DNA encoding for epitope-tagged TATA-box binding protein (TBP), the production of transgenic animals which express epitope-tagged TBP and use thereof for affinity purification of transcription factors and transcription complexes from a variety of eukaryotic tissues and cell-types. ... 12/01/05 - 20050268349 - Transgenic mice containing brain-specific membrane-anchored protein gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a BSMAP gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 12/01/05 - 20050268348 - Mouse model for psoriasis and psoriatic arthritis A mouse that is deficient for c-Jun and JunB in the epidermis or in which deletion of c-Jun and JunB can be specifically induced in the epidermis, and methods for obtaining such mice. The mice and keratinocytes derived therefrom are useful as an animal model for psoriasis and psoriatic arthritis. ... 11/24/05 - 20050262580 - Transgenic mouse with a targeted deletion of elovl4 gene The present invention relates to a transgenic mouse whose genome is heterozygous for a disruption of a native Elovl4 gene. The transgenic mouse and cells derived therefrom can be used to screen drug or food supplement for the treatment and prevention of visual disorders such as Stargardt-like dominant macular dystrophy. ... 11/17/05 - 20050257280 - Nonhuman model animal nonresponsive to endotoxin and lipoprotein or lipopeptide The present invention relates to a non-human animal model non-responsive to bacterial components such as lipoproteins/lipopeptides, peptidoglycans and endotoxins, being useful to elucidate the function of TIRAP being an adaptor protein of TLR family; a substance promoting or suppressing the response to bacterial components using these non-human animal models non-responsive ... 11/17/05 - 20050257279 - Agouti-related protein deficient cells, non-human transgenic animals and methods of selecting compounds which regulate energy metabolism Cells and non-human transgenic animals have been engineered to be deficient in the gene encoding agouti-related protein (AgRP). AgRP deficient transgenic animals have a reduced day time respiratory quotient (RQ), indicating that AgRP is involved in the regulation of energy metabolism, resulting in the reduced usage of fat as an ... 11/10/05 - 20050251874 - Mice lacking alpha 1g showing enhanced novelty-seeking and alcohol preference and therapeutic methods for mood disorders by modulating alpha 1g t-type calcium channels The present invention relates to a novel use of an α1G T-type calcium channel transgenic mouse as a nervous disease model, more particularly, a novel use of a mouse deficient in α1G T-type calcium channel showing novelty-seeking and alcohol preference as a nervous disease model for human nervous related diseases ... 11/10/05 - 20050251873 - Ace2 activation for treatment of heart, lung and kidney disease and hypertension The invention relates to ACE2 activating compounds for prevention and treatment of cardiovascular disease, kidney disease, lung disease and hypertension. The invention also includes methods of diagnosing cardiovascular disease, kidney disease, lung disease and hypertension by measuring ACE2 expression or nucleotide polymorphism analysis. ... 10/27/05 - 20050241012 - Multigene profiling in the kidney to tailor drug therapy Provided are compositions, transgenic animals and methods for screening and analyzing drugs for toxicity and clearance. Such methods include creating a transgenic animal that lacks expression of two or more slc22 family member—organic ion transporters. Further disclosed are methods useful in determining a subjects sensitivity and a drugs efficacy based ... 10/20/05 - 20050235373 - Iex-1 knockout animals The invention provides methods and materials related to animals having a disrupted IEX-1 sequence. For example, the invention provides homozygous knockout (IEX-1−/−) animals and heterozygous (IEX-1∓) animals. ... 10/20/05 - 20050235372 - Nonhuman model animal unresponsive to immunopotentiating synthetic compound The present invention relates to provide a non-human animal model unresponsive to a synthetic compound wherein a gene function encoding TLR7 that recognizes an immunopotentiating synthetic compound such as imidazoquinoline lacks on is genomic locus. Whole or part of a gene fragment of a gene site including an intracellular region ... 10/06/05 - 20050223420 - Inducible heart attack animal model An animal model of coronary heart disease has been developed where myocardial infarct can be induced by altering the animal's diet. In all embodiments, this animal model is a result of reduced activity of scavenger receptor class BI (SR-BI) and apolipoprotein E (ApoE). In a preferred embodiment, the model is ... 10/06/05 - 20050223419 - Mice which are +/- or -/- for the elastin gene as models for vascular disease Elastin, the main component of arterial extracellular matrix, was thought to have a purely structural role. Consistent with this view, elastin hemizygous mice maintain arterial extensibility by increasing the number of elastic lamellae during development. However, mice lacking elastin die of obstructive arterial pathology. This pathology results from subendothelial proliferation ... 09/29/05 - 20050216966 - Method of constructing germline chimeric animal The present invention provides a method for efficiently producing a germ-line chimeric animal and a method for conveniently producing a heterozygous animal and a homozygous animal. Specifically, a chimeric animal wherein germ cells are derived from introduced ES cells is produced by injecting embryonic stem cells (ES cells) into an ... 09/22/05 - 20050210540 - Glyt1 transgenic mouse The present invention provides genetic constructs and methods for producing transgenic non-human animals comprising within their genome transgenic DNA encoding GLYT1. These transgenic animals could be further used to generate transgenic animals which produce more active GLYT1. Also provided are transgenic animals producing more GLYT1 protein, as well as the ... 09/22/05 - 20050210539 - Methods of preforming homologous recombination based modification of nucleic acids in recombination deficient cells and use of the modified nucleic acid products thereof A simple method for modifying genes in a recombination deficient host cell is disclosed. Such modifications include generating ins |